Endoscopic Therapy in Barrett Esophagus and Early Cancer

Video
Conference|American Society of Clinical Oncology Annual Meeting (ASCO)

This video reviews the use of endoscopic therapy for the management of Barrett esophagus and early esophageal cancer.

In this video, Prateek Sharma, MD, of the University of Kansas Medical Center, discusses highlights from his presentation on endoscopic therapy for the management of Barrett esophagus and early esophageal cancer.

Sharma spoke on this topic at an extended education session, “Management of Complex Upper Gastrointestinal Cases: Implementation of Best Evidence,” at the 2017 American Society of Clinical Oncology (ASCO) Annual Meeting, on June 2 in Chicago.

Recent Videos
Combining sotorasib with panitumumab may reduce the burden of disease in patients with KRAS G12C-mutated metastatic colorectal cancer.
Findings from the CodeBreak 300 study have cemented sotorasib/panitumumab as a third-line treatment option for KRAS G12C-mutated colorectal cancer.
Sotorasib plus panitumumab may offer improved survival compared with previously approved treatment options in KRAS G12C-mutated colorectal cancer.
Additional local, regional, or national policy may bolster access to screening for colorectal cancer, according to Aasma Shaukat, MD, MPH.
The mechanism of action for daraxonrasib inhibits effectors and signaling while forming a relatively unstable tri-complex with codon 12 mutations.
Almost all patients evaluable for efficacy reported a decrease in ctDNA when treated with daraxonrasib for RAS-mutant pancreatic ductal adenocarcinoma.
Additional progression-free survival data from the phase 3 BREAKWATER trial will be presented at future meetings.
As patients are nearing the end of life, different management strategies, such as opioids, may be needed to help mitigate pain or fatigue.
Kelley A. Rone, DNP, RN, AGNP-c, highlights the importance of having end-of-life discussions early in a patient’s cancer treatment course.
Advocacy groups such as Cancer Support Community and the Leukemia & Lymphoma Society may help support patients with CML undergoing treatment.
Related Content
Clinicians Consider Identification, Management of RCC Through the Patient’s Eyes

Clinicians Consider Identification, Management of RCC Through the Patient’s Eyes

ONCOLOGY Staff
March 8th 2025
Article

James Zoeller discussed various aspects of his cancer care after a RCC diagnosis with Hannah D. McManus, MD, and Allison Brown, BSN, RN, RN-BC.

The approval of sotorasib plus panitumumab is a “welcome step” in KRAS G12C-mutated colorectal cancer, according to Marwan G. Fakih, MD.

Sotorasib Combo Approval May Address Novel Therapy Need in KRAS G12C+ CRC

Marwan G. Fakih, MD
February 24th 2025
Podcast

The approval of sotorasib plus panitumumab is a “welcome step” in KRAS G12C-mutated colorectal cancer, according to Marwan G. Fakih, MD.

EC Approves Nivolumab/Ipilimumab in Frontline Unresectable HCC

EC Approves Nivolumab/Ipilimumab in Frontline Unresectable HCC

Tim Cortese
March 7th 2025
Article

The CheckMate 9DW trial found that nivolumab and ipilimumab elicited a median OS of 23.7 months compared with 20.6 months from lenvatinib or sorafenib.

Kelley A. Rone, DNP, RN, AGNP-c, provides perspective on approaching end-of-life conversations with patients with GI cancers.

Educating Patients and Clinicians on End-of-Life Care and Discussions

Kelley A. Rone, DNP, RN, AGNP-c
November 11th 2024
Podcast

Kelley A. Rone, DNP, RN, AGNP-c, provides perspective on approaching end-of-life conversations with patients with GI cancers.

ITM-11 Demonstrates Superior PFS Vs Everolimus in SSTR+ GEP-NETs

ITM-11 Demonstrates Superior PFS Vs Everolimus in SSTR+ GEP-NETs

Tim Cortese
March 6th 2025
Article

In the phase 3 COMPETE trial, ITM-11 met its primary end point of PFS and showed a favorable trend with respect to OS in GEP-NETs.

The safety profile of trastuzumab deruxtecan in the phase 3 DESTINY-Gastric04 trial was consistent with the established safety profile of the agent.

Trastuzumab Deruxtecan Improves Survival in HER2+ Metastatic Gastric Cancer

Roman Fabbricatore
March 5th 2025
Article

The safety profile of trastuzumab deruxtecan in the phase 3 DESTINY-Gastric04 trial was consistent with the established safety profile of the agent.